Chemical-genetic disruption of clathrin function spares adaptor complex 3–dependent endosome vesicle biogenesis

Stephanie A. Zlatic, Emory University
Emily J. Grossniklaus, Emory University
Pearl V. Ryder, Emory University
Gloria Salazar, Emory University
Alexa L Mattheyses, Emory University
Andrew A. Peden, University of Sheffield
Victor Faundez, Emory University

Journal Title: Molecular Biology of the Cell
Volume: Volume 24, Number 15
Publisher: American Society for Cell Biology | 2013-08-01, Pages 2378-2388
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1091/mbc.E12-12-0860
Permanent URL: http://pid.emory.edu/ark:/25593/fm4dr

Final published version: http://www.molbiolcell.org/content/24/15/2378

Copyright information:
© 2013 Zlatic et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License (http://creativecommons.org/licenses/by-nc-sa/3.0/).

Accessed December 14, 2018 6:17 PM EST
Chemical-genetic disruption of clathrin function spares adaptor complex 3–dependent endosome vesicle biogenesis

Stephanie A. Zlatic, Emily J. Grossniklaus, Pearl V. Ryder, Gloria Salazar, Alexa L. Mattheys, Andrew A. Peden, and Victor Faundez

ABSTRACT A role for clathrin in AP-3–dependent vesicle biogenesis has been inferred from biochemical interactions and colocalization between this adaptor and clathrin. The functionality of these molecular associations, however, is controversial. We comprehensively explore the role of clathrin in AP-3–dependent vesicle budding, using rapid chemical-genetic perturbation of clathrin function with a clathrin light chain–FKBP chimera oligomerizable by the drug AP20187. We find that AP-3 interacts and colocalizes with endogenous and recombinant FKBP chimeric clathrin polypeptides in PC12-cell endosomes. AP-3 displays, however, a divergent behavior from AP-1, AP-2, and clathrin chains. AP-3 cofractionates with clathrin-coated vesicle fractions isolated from PC12 cells even after clathrin function is acutely inhibited by AP20187. We predicted that AP20187 would inhibit AP-3 vesicle formation from endosomes after a brefeldin A block. AP-3 vesicle formation continued, however, after brefeldin A wash-out despite impairment of clathrin function by AP20187. These findings indicate that AP-3–clathrin association is dispensable for endosomal AP-3 vesicle budding and suggest that endosomal AP-3–clathrin interactions differ from those by which AP-1 and AP-2 adaptors productively engage clathrin in vesicle biogenesis.

INTRODUCTION

Exocytic and endocytic compartments exchange components and maintain their composition by means of carriers, some of which are vesicles (Bonifacino and Glick, 2004; De Matteis and Luini, 2011). The generation of vesicles and the selective loading of proteins and lipids into them require diverse monomeric and heteromeric cytosolic coats. Among the latter, heterotetrameric adaptor complexes AP-1–5 specify distinct trafficking routes. AP-1–5 adaptors comprise four subunits of various sizes: two large subunits, β1-5 and α, γ, δ, ε, or ζ; one medium-size, μ1-5 subunit; and a small, σ1-5 subunit. All of these heterotetrameric adaptor complexes share the ability to recognize specific sorting signals in the cytosolic domains of membrane proteins. Some adaptors have in common the capacity to bind phosphoinositides, GTPases, and proteins that act as modules to connect a nascent vesicle to diverse machineries. These include, but are not limited to, membrane deformation, the cytoskeleton, or the recognition of specialized cargoes. In contrast, these adaptor complexes differ in their ability to bind clathrin and/or corediment with clathrin-coated vesicles (Kirchhausen, 2000; Bonifacino and Traub, 2003; Bonifacino and Glick, 2004; Robinson, 2004; Hirst et al., 2011; McMahon and Boucrot, 2011).

Clathrin heavy-chain and the associated clathrin light-chain polypeptides assemble into triskelia, which are the structural building blocks of clathrin cages. These cages encase and help to concentrate adaptors with their bound membrane cargoes and other associated factors in the transition from a clathrin-coated membrane pit into a clathrin-coated vesicle bud. AP-1 and AP-2 bind to the
clathrin heavy chain via the appendages of β adaptins (Kirchhausen, 2000; Bonifacino and Traub, 2003; Bonifacino and Glick, 2004; Robinson, 2004; Hirst et al., 2011; McMahon and Boucrot, 2011; Willox and Royle, 2012). Extensive biochemical, structural, and functional evidence indicates that clathrin association with AP-1 and AP-2 is necessary for vesicle formation by these adaptors (Kirchhausen, 2000; Bonifacino and Traub, 2003; Bonifacino and Glick, 2004; Robinson, 2004; Hirst et al., 2011; McMahon and Boucrot, 2011; Willox and Royle, 2012). In contrast, adaptor complexes AP-4 and AP-5 do not cofractionate with clathrin-coated vesicles and may function independently of clathrin, although more research on these complexes is needed to establish certainty (Hirst et al., 1999, 2013; Borner et al., 2006, 2012). A more thoroughly studied adaptor, the AP-3 complex, has a debatable relationship with clathrin. A functional equivalence for AP-3 with AP-1 or AP-2 has been inferred based on biochemical interactions and colocalization of AP-3 with clathrin. Nonetheless, the precise functional role of clathrin in AP-3 vesicle generation has been a matter of dispute since AP-3’s discovery (Dell’Angelica et al., 1997, 1998; Faundez et al., 1997, 1998; Shi et al., 1998; Blondeau et al., 2004; Peden et al., 2004; Theos et al., 2005; Borner et al., 2006; Salazar et al., 2009; Kural et al., 2012).

AP-3 generates vesicles that traffic membrane proteins from endosomes to lysosomes, lysosome-related organelles, or synaptic vesicles. Defects in this vesicle formation machinery translate into the type 2 Hermansky–Pudlak syndrome in humans, a disease that shares a similar constellation of phenotypes with AP-3–null mice and flies, the most prominent of these being pigment dilution (Wei, 2006; Wei and Li, 2012; Dangioti and Galli, 2007; Newell-Litwa et al., 2007; Raposo and Marks, 2007; Raposo et al., 2007). In this study, we comprehensively explore the role of clathrin in AP-3–dependent vesicle budding, using rapid chemical-genetic perturbation of clathrin function. We recapitulate key biochemical and colocalization findings by others. However, despite a clathrin and AP-3 interaction, AP-3–dependent budding from endosomes is resistant to rapid clathrin inhibition in whole-cell assays. We propose that the interaction between clathrin and AP-3 at endosomes fulfills functions distinct from the canonical role of clathrin in AP-1– and AP-2–dependent vesicle formation.

RESULTS

We sought to test the function of clathrin interactions with the adaptor complex AP-3, using chronic and acute chemical-genetic perturbations of clathrin function. We hypothesized that if AP-3 vesicle budding from endosomes requires clathrin, as is the case for AP-1 and AP-2, then chronic and acute clathrin perturbation should similarly affect the content of these three adaptors in clathrin-coated vesicle fractions. We used short hairpin RNA (shRNA) down-regulation of clathrin heavy chain as a mean to chronically perturb clathrin. Acute interference of clathrin function was achieved with a clathrin light-chain chimera carrying in tandem an mCherry tag and an FKBP oligomerization domain (mCh-FKBP-CLC). Induction of mCh-FKBP-CLC quaternary structures impairs clathrin function in minutes after addition of the bivalent FKBP-binding agent AP20187 by trapping clathrin polypeptides and their associated molecules on membranes (Moskowitz et al., 2003; Deborde et al., 2008; Zlatic et al., 2011). This rapid onset of effects is in contrast with clathrin heavy-chain down-regulation by shRNA, which takes several days to attain clathrin function inhibition.

Clathrin and AP-3 interactions have been documented by means of in vitro pull-downs with the hinge-ear domain of AP-3 β3 subunits, as well as by AP-3 enrichment in clathrin-coated vesicles (Dell’Angelica et al., 1998; Blondeau et al., 2004; Borner et al., 2006; Salazar et al., 2009). Under knockdown conditions, clathrin vesicle formation is impaired, leading to reduced content of proteins copurifying with clathrin-coated vesicles including AP-3 subunits (Borner et al., 2006). We revisited these criteria in HEK293 cells and PC12 cells expressing mCh-FKBP-CLC to validate this recombiant tool. We used shRNA-mediated clathrin heavy-chain knockdown in HEK cells, followed by clathrin-coated vesicle isolation, to determine whether AP-3 adaptor subunits could be considered components of clathrin-coated vesicles in cells transiently expressing mCh-FKBP-CLC. Equal protein loads from control knockdown and clathrin heavy-chain down-regulated clathrin-coated vesicle fractions were analyzed by SDS–PAGE and Western blot (Figure 1A, A and B). Clathrin heavy chain was enriched in clathrin-coated vesicle fractions (Figure 1A, compare lanes 1 and 3, asterisk), and the content of clathrin heavy chain and other fraction polypeptides decreased after clathrin heavy-chain down-regulation (Figure 1A, compare lanes 3 and 4). In addition, mCh-FKBP-CLC and adaptor complexes AP-1–3 were enriched in clathrin-coated vesicle fractions (Figure 1B, compare lanes 1 and 6), and their presence in clathrin-coated vesicle enriched fractions was similarly sensitive to shRNA clathrin heavy-chain down-regulation (Figure 1B, compare lanes 6 and 12). AP-3 content in clathrin-coated vesicle enriched fractions was insensitive to down-regulation of BLOC-1 complexes, a major AP-3 interactor (Supplemental Figure S1; Di Pietro et al., 2006; Salazar et al., 2009; Gokhale et al., 2012; Lee et al., 2012). These results are compatible with the hypothesis that a subset of clathrin-coated vesicles may contain the adaptor complex AP-3.

We further tested the possible association of AP-3 with clathrin by communomagnetic precipitations. We performed cross-linking with the homo-bifunctional cross-linker dithiobis-succinimidyl propionate (DSP) in intact cells (Lomant and Fairbanks, 1976; Zlatic et al., 2010). Our rationale was to chemically stabilize putative clathrin–AP-3 associations in intact cells and use stringent isolation conditions to prevent cell-free clathrin–AP-3 associations after cell solubilization. mCh-FKBP-CLC HEK293 cells were treated in the absence or presence of DSP, and detergent cell extracts were incubated with magnetic beads containing antibody directed against clathrin light chain (Figure 1C), clathrin heavy chain (Figure 1D), or AP-3 β (Figure 1E). Isolated immunocomplexes were analyzed by Western blot. Clathrin light-chain immunocomplexes coisolated with both clathrin heavy chain and the AP-3 adaptor subunit β3 (Figure 1C, lane 3). Similarly, isolation of clathrin heavy-chain immunocomplexes precipitated both clathrin light chain and the AP-3 adaptor subunit β3, the latter only in the presence of DSP cross-linker (Figure 1D, compare lanes 5 and 6). In addition, the association between clathrin chains and AP-3 could be detected in reverse magnetic precipitations where AP-3 was isolated with AP-3 clathrin light chain (Figure 1E). These results are compatible with the hypothesis that a subset of clathrin-coated vesicles may contain the adaptor complex AP-3.
Our biochemical results suggested a low extent of overlap between clathrin and AP-3 polypeptides. Our goal was to quantitatively assess the extent to which clathrin and AP-3 associate in PC12 cells expressing mCherry-FKBP-CLC at steady state, in particular in early endosome compartments. Thus we performed indirect immunofluorescence experiments with high-resolution deconvolution microscopy or superresolution structured illumination microscopy (Figures 2 and 3, Supplemental Figures S2–S4, and Supplemental Movie S1). Polypeptides were detected with antibodies against AP-3 δ, clathrin light chain, or mCherry. We previously demonstrated that mCh-FKBP-CLC occupies nearly all clathrin heavy chain–positive structures in HEK293 cells (Zlatic et al., 2011). Similarly, mCh-FKBP-CLC and clathrin heavy-chain signals extensively overlapped in PC12 cells, as revealed by deconvolution microscopy (74 ± 8.6% of all clathrin heavy-chain pixels present in a cell, n = 10; data not shown), validating recombinant clathrin light chain as a marker of clathrin coats in this neuroendocrine cell. In contrast, only 10–20% of all clathrin-positive structures present in a PC12 cell overlapped with AP-3 pixels (Figures 2A and 3 and Supplemental Figure S2). Structures for which the AP-3 and clathrin overlapped in images...
acquired using deconvolution microscopy were imaged using super-resolution structured illumination microscopy (SIM). SIM provides a theoretical doubling of spatial resolution above wide-field deconvolution (~120 nm, x-y; 300 nm, z). Analysis of SIM images showed that the overlap of clathrin and AP-3 remained (SIM, Figure 2, B and C). Arrows draw attention to the same discrete puncta in A and B. Dotted lines outline area of colocalization. Scale bar, 0.5 μm. (C2) A 45° rotation of C1 around a vertical axis. See Supplemental Movie S1.

In the following experiments, we specifically focused on early endosomal compartments since these endosomes bud a biochemically and pharmacologically tractable microvesicle population generated by an AP-3–dependent mechanism (Faundez et al., 1997, 1998; Faundez and Kelly, 2000; Clift-O’Grady et al., 1998; Shi et al., 1998). To examine the subcellular distribution of clathrin and AP-3 adaptor in endosomes, we determine the extent of AP-3 signal overlap with clathrin in endosomes identified with the early endosome marker EEA1 (Figure 3). We performed triple indirect immunofluorescence experiments with antibodies against AP-3 δ, the mCherry tag in mCh-FKBP-CLC, and EEA1 using high-resolution deconvolution microscopy. AP-3 and CLC colocalized in early endosomes (Figure 3). Moreover, the extent of AP-3–CLC signal overlap significantly increased from 20.7 ± 7.1% (average ± SEM) to 25.9 ± 6.6% after trapping clathrin chains on membranes by the addition of AP20187 (Figure 3, A–C). This increased overlap after AP20187 occurred at the expense of an accumulation of clathrin polypeptides on endosomes (Figure 3, A, B, and D) rather than an increase of AP-3 on these organelles (Figure 3, A, B, and E). We further tested the presence of AP-3 and clathrin overlapping domains in endosomes by transiently expressing an enhanced green fluorescent protein (EGFP)-tagged Rab5 Q79L mutant in PC12 cells stably expressing mCh-FKBP-CLC (Supplemental Figures S3 and S4). Molecules were detected in fixed cells using antibodies against EGFP, mCherry, and AP-3 δ. The EGFP-tagged Rab5 Q79L mutant allowed us to unequivocally identify early endosomes for quantitative analysis of AP-3 and clathrin subcellular overlap. Rab5 Q79L early endosomes were identified by their enlarged EGFP perimeter (Supplemental Figure S3). In these endosomes, we determined the percentage of their perimeter occupied by either clathrin or AP-3. mCh-FKBP-CLC covered 35 ± 5.2% of the EGFP-Rab5 Q79L–labeled perimeter (Supplemental Figure S4A, column 1). Similarly, AP-3 was present in 30.5 ± 5.9% of the EGFP-labeled endosome limiting membrane (Supplemental Figure S4A, column 3), the extent of which was not significantly modified by the addition of AP20187 (Supplemental Figure S4A, column 4). Of importance, a fraction of the entire AP-3 signal present in the endosome perimeter overlapped with mCh-FKBP-CLC (15.6 ± 3.8%; Supplemental Figure S4A, column 5). This result is in good agreement with previous quantitative electron immunomicroscopy data indicating that not all AP-3 budding profiles in early endosomes are decorated with clathrin in cell types other than PC12 cells (Pedersen et al., 2004; Theos et al., 2005). These results indicate that a pool of AP-3 overlaps with clathrin light chain in early endosomes, the site of origin for AP-3 microvesicles in PC12 cells.

PC12 cells generate clathrin-coated vesicles from the plasma membrane by a mechanism that is AP-2 and clathrin dependent yet brefeldin A insensitive (Figure 4, step 1). These clathrin-coated vesicles feed to early endosomes, where synaptic-like microvesicles (SLMVs) bud by a mechanism that instead requires AP-3 and ARF1. This AP-3 budding pathway is sensitive to brefeldin A (Figure 4, step 2; Faundez et al., 1997, 1998; Faundez and Kelly, 2000; Shi et al., 1998). Synaptic membrane proteins sorted into these SLMVs, such as SV2 or VAMP7, sequentially use these two vesicle-generation steps, whose vesicle products can be distinguished by their distinctive sedimentation properties (Figure 4). This allows selective isolation of clathrin-coated vesicles and SLMVs. We took advantage of features distinguishing these pathways to selectively test the requirement of clathrin in the budding of AP-2 and AP-3 vesicles in PC12 cells stably expressing mCh-FKBP-CLC. We first asked whether the content of adaptor subunits cosedimenting with clathrin-coated vesicles was sensitive to the acute inhibition of clathrin function in mCh-FKBP-CLC–expressing PC12 cells. Our hypothesis predicted that if AP-3 vesicle budding requires clathrin, then acute clathrin perturbation should similarly affect the content of adaptors in clathrin-coated vesicle fractions. Stably transfected mCh-FKBP-CLC PC12 cells were treated for 2 h with vehicle control or AP20187 to perturb clathrin function. We determined the global effectiveness of AP20187 treatment by the redistribution of clathrin and AP-3 toward the perinuclear area after drug incubation (Supplemental Figure S2), the accumulation of clathrin in EEA1-positive endosomes (Figure 3), and a reduction in endosome perimeter after drug addition (Supplemental Figure S4D, and data not shown; Deborde et al., 2008; Zlatic et al., 2011). Clathrin-coated vesicle–enriched fractions were prepared from vehicle and AP20187-treated cells and fraction contents analyzed by SDS–PAGE and Western blot (Figure 5A). AP20187 selectively decreased a major polypeptide of ~180 kDa in clathrin-coated vesicle fractions resolved by SDS–PAGE. We confirmed this band as clathrin heavy chain by immunoblot (Figure 5, A and B).
Concurrent with clathrin heavy chain depletion, we detected decreased content of endogenous clathrin light chain and recombinant mCh-FKBP-CLC in clathrin-coated vesicle–enriched fractions (Figure 5C, compare lanes 6 and 12). Of importance, the content of AP-1 γ adaptin and AP-2 α adaptin were similarly reduced in clathrin-coated vesicle fractions isolated from AP20187-treated cells (Figure 5, B and C, compare lanes 1 and 2, and 6 and 12, respectively, and D). Clathrin-coated vesicle cargoes synaptobrevin 2, syntaxin 7 (Blondeau et al., 2004; Takamori et al., 2009), and VAMP7 (Blondeau et al., 2009) were reduced after AP20187 treatment, a further indication that plasma membrane clathrin-coated vesicle formation was impaired by mCh-FKBP-CLC oligomerization (Figure 5C, compare lanes 6 and 12). Strikingly, even though treatment with AP20187 impaired the formation of AP-1 and AP-2 clathrin-coated vesicles, we observed an increase in the levels of AP-3 in clathrin-coated vesicle enriched–fractions as determined by immunoblot with antibodies against β3, δ, and σ3 subunits (Figure 5, B and C, compare lanes 1 and 2, and 6 and 12, respectively, and D). These results demonstrate that clathrin-coated vesicle formation by AP-1– and AP-2–dependent mechanisms is robustly impaired by acute clathrin oligomerization in PC12 cells expressing mCh-FKBP-CLC. Our findings suggest, however, that a putative clathrin–AP-3 interaction differs from other clathrin–adaptor interactions after acute clathrin function perturbation. This differential behavior of AP-3 content in clathrin-coated vesicle fractions after AP20187 treatment raises the question of whether it also reflects a differential requirement of clathrin in endosome AP-3 vesicle generation.

To test the function of clathrin interactions with the adaptor complex AP-3, we took advantage of PC12 cells expressing mCh-FKBP-CLC and the pharmacological sensitivity of AP-3 vesicle budding to brefeldin A. The sequential organization of AP-2 and AP-3 budding steps has so far precluded a direct test of clathrin’s role in endosome SLMV formation using long-term clathrin perturbations such as shRNA or expression of clathrin heavy-chain recombinant fragments (Figure 4). Therefore we used pharmacological epistasis between the brefeldin A and AP20187 blocks in mCh-FKBP-CLC–expressing PC12 cells to selectively assess a role of clathrin in AP-3 vesicle generation. Brefeldin A completely and reversibly inhibits SLMV formation by AP-3 while sparing the generation of AP-2 vesicles (Figure 4, steps 1 and 2; Faundez et al., 1997; Shi et al., 1998). If the AP-3 budding step requires clathrin, we reasoned that after a SLMV brefeldin A block, a brefeldin A washout in the presence of AP20187 should prevent de novo SLMV generation. In contrast, if clathrin is dispensable for AP-3 vesicle budding, then a brefeldin A washout in the presence of AP20187 should lead to a complete recovery of SLMV formation. We used VAMP7 and SV2 to track SLMV presence and their formation after pharmacological blockages. We selected these two transmembrane proteins because they are enriched in SLMV and mostly localize to endosome compartments at steady state in cells of the neural lineage (Newell-Litwa et al., 2009). In addition, VAMP7 is an AP-3 cargo that directly binds AP-3 (Martinez-Arca et al., 2003; Kent et al., 2012), mCh-FKBP-CLC–expressing PC12 cells were incubated in the presence of vehicle or brefeldin A for 2 h, and SLMVs were isolated by differential centrifugation followed by glycerol velocity sedimentation. Glycerol velocity gradients resolve SLMVs by size as a peak in the middle of the gradient (Figure 6, fractions 8–10; Clift-O’Grady et al., 1998). Brefeldin A decreased SLMVs as determined by VAMP7 and SV2 gradient content (Figure 6, A–C and A1–C1, open circles). This brefeldin A block was released after a SLMV brefeldin A block (Figure 6, B and B1, black circles). Of note, continuous incubation of cells in AP20187 instead of vehicle for 2 h had no effect on the reversibility of the brefeldin A washout (Figure 6, C and C1, black circles). This outcome was not due to either a reversal of the brefeldin A block after 4 h of incubation (Supplemental Figure S5) or a redistribution of mCh-FKBP-CLC chains away from endosomes after AP20187. In fact, AP20187 incubation neither modified clathrin or AP-3 nor changed AP-3-clathrin light-chain interactions.
To test this hypothesis, we focused on fibroblasts carrying the suspected in PC12 cells and other cell types may not follow a canonical formation suggests that interactions between AP-3 and clathrin de- are functional.

and are in agreement with the previous contention that AP-3 com- PC12 cells is dispensable for the budding of AP-3-derived SLMV

2008; Zlatic

overlap in the limiting membrane of enlarged early endosomes (Supplemental Figure S4A, compare even and odd columns) over a wide range of clathrin content per endosome and endosome size (Supplemental Figure S4, B and C). This observation is consistent with the described AP20187-dependent trapping of clathrin poly- peptides on membranes (Moskowitz et al., 2003; Deborde et al., 2008; Zlatic et al., 2011). These results demonstrate that the bio-chemical interaction between AP-3 and clathrin chains found in PC12 cells is dispensable for the budding of AP-3-derived SLMV and are in agreement with the previous contention that AP-3 com-plexes carrying mutations in the β3 putative clathrin binding domain are functional.

The dispensability of clathrin function for AP-3–dependent SLMV formation suggests that interactions between AP-3 and clathrin detected in PC12 cells and other cells types may not follow a canonical association mechanism between the ear domain of the β subunit of the adaptor and clathrin terminal domain (Wilcox and Royle, 2012). To test this hypothesis, we focused on fibroblasts carrying the β3A mutation pearl (Ap3bTpa/pa). These cells carry a hypomorphic mutation in the AP-3 complex that affects the sorting of AP-3 cargoes. We used Ap3bTpa/pa cells or Ap3bTpa/pa rescued with either recom- binant wild-type β3A or β3A mutations ablat- ing putative clathrin-binding determinants (clathrin box) in the β3A hinge-ear domain to test whether an AP-3–clathrin interaction is sensitive to mutagenesis of the β3 clathrin box. These mutations included discrete changes in the β3A clathrin-binding sequence Θ175LLDLQ822 (β3Aβ17AAAA), a deletion of the Θ175LLDLQ822 clathrin box (β3AΔ807-831), and a truncation of the entire β3A ear domain (β3AΔ80Stop). With the excep- tion of β3AΔ80Stop, all other β3A clathrin box mutants rescued a mis-sorting phenotype in Ap3bTpa/pa cells (Peden et al., 2002). We performed DSP cross-linking in intact cells followed by immuno-magnetic isolation of AP-3 complexes with δ antibodies. The δ adaptin antibodies precipitated δ3 subunits from Ap3bTpa/pa and notably low levels of clathrin in the presence of DSP but not BLOC-1 subunits detected with antibodies against paladin (Figure 7, compare

lanes 1 and 2). These δ-δ3 polypeptides correspond to the reported δ-δ3 adaptor hemicomplexes described in Ap3bTpa/pa cells (Peden et al., 2002). We used the BLOC-1 complex, an AP-3 interactor, and

FIGURE 4: Model of acute pharmacological perturbation to clathrin and AP-3 in PC12 cells stably expressing mCh-FKBP-CLC. Step 1: AP-2 vesicles bud from the plasma membrane (PM) in a clathrin-dependent manner. Acute AP20187 treatment perturbs FKBP-CLC, and thus clathrin function, in these cells. AP-2-clathrin coated vesicles (CCV) feed into endosomal organelles. Step 2: AP-3 vesicles, presumably coated with clathrin, bud from an early endosomal compartment to form SLMVs. Acute treatment of these cells with brefeldin A disrupts AP-3 vesicle formation. We tested whether acute treatment of these cells with AP20187 similarly affects SLMV formation. We hypothesized that if clathrin is required for AP-3–derived SLMV formation, then AP20187 treatment after release of a brefeldin A block in SLMV formation should further prohibit SLMV formation.

FIGURE 5: AP-3 levels increase in clathrin-coated vesicle fractions after acute clathrin function perturbation. (A) Coomassie stain of SDS–polyacrylamide gel loaded with fractions of CCVs isolated from PC12 cells stably expressing mCh-FKBP-CLC. Cells were treated for 2 h with vehicle (lanes 1–6) or the drug AP20187 to acutely perturb clathrin function (lanes 7–12). Arrows direct attention to a band that runs consistent with clathrin heavy-chain molecular weight. (B) Western blot of CCVs fraction from A. Arrow draws attention to a band in clathrin heavy-chain immunoblot that shows a decrease in the CCV fraction from cells with acute clathrin perturbation compared with vehicle control. Decrease in clathrin signal from CCV fraction of drug-treated cells indicates that acute clathrin perturbation affects clathrin vesicle formation. (C) Western blots of clathrin-coated vesicle isolation fractions from PC12 cells stably expressing mCherry-FKBP-CLC treated for 2 h with either vehicle control (lanes 1–6) or the drug AP20187 to perturb clathrin function (lanes 7–12). (D) Densitometry quantification of CCV fraction from three biological replicates each with at least two technical replicates of clathrin coated–vesicle isolations in PC12 cells stably expressing mCherry-FKBP-CLC and treated for 2 h with either vehicle control or AP20187 to acutely perturb clathrin function. AP-3 subunits display significantly higher signals in CCV fractions from AP20187-treated cells compared with vehicle control–treated cells despite decreases in other adaptor subunits like AP-1γ and AP-2α. The extent of decrease in AP-1γ and AP-2α in CCV fraction treated with AP20187 compared with control is similar, as highlighted by the nonsignificance when these two are compared (not significant [NS]). CCV, clathrin-coated vesicle fraction; H, homogenate; IB, immunoblot; P1, pellet 1; P2, pellet 2; S1, supernatant 1; S2, supernatant 2; p values, analysis of variance multiple comparisons with Student–Newman–Keuls post hoc test.
These results indicate that the active clathrin-binding determinants in the complexes was not sensitive to any of the mutations ablating putative clathrin-binding determinants in the β3A hinge-ear domain. These results indicate that the β3A hinge-ear domain is not necessary for clathrin interactions with cross-linked AP-3 complexes. Our results suggest that AP-3 diverges from the model by which AP-1 and AP-2 adaptors bind to clathrin cages for vesicle biogenesis via the C-terminus of β adaptins with the terminal domain of clathrin-heavy chain (Lemmon and Traub, 2012).

**DISCUSSION**

We explored the role of clathrin in AP-3-dependent vesicle budding by means of long-term clathrin shRNA down-regulation and rapid chemical-genetic perturbation of clathrin function. Down-regulation of clathrin heavy chain has been used to assess whether components enriched in clathrin-coated vesicle fractions truly reside in these organelles. This approach has been validated in HeLa cells using quantitative mass spectrometry alone or in combination with this observation as evidence of clathrin dispensability in AP-3 SLMV budding from endosomes. We examined alternative interpretations that could also explain our brefeldin A-AP20187 pharmacological epistasis results. We asked 1) whether AP-3 interacts and colocalizes with AP-1 and AP-2. Low principles similar to those by adaptors indeed requires clathrin to generate vesicles and acute clathrin function perturbation deﬁnes the “anomalous” AP-3 behavior prompted us to reevaluate whether AP-3 induced requires clathrin to generate vesicles and whether clathrin–AP-3 interactions follow principles similar to those by adaptors AP-1 and AP-2.

Our findings in PC12 cells indicate that acute perturbation of clathrin with a mCh-FKBP-CLC chimera does not prevent the formation of AP-3 vesicles from endosomes after a brefeldin A block. We interpreted the levels of α3 adaptin precipitated by δ antibodies as indications of reassembled AP-3 complexes with different recombinant β3A subunits (D) (Pietro et al., 2006; Salazar et al., 2006, 2009; Gokhale et al., 2012). The content of clathrin precipitating with δ adaptin antibodies increased in all Ap3b1lo−/− cells where AP-3 complexes were reassembled by reexpression of recombinant β3A chains (Figure 7, compare lane 2 with lanes 4, 6, 8, and 10). Of importance, this increase in clathrin coprecipitation with reassembled AP-3 complexes was not sensitive to any of the mutations ablating putative clathrin-binding determinants in the β3A hinge-ear domain. These results indicate that the β3A hinge-ear domain is not necessary for clathrin interactions with cross-linked AP-3 complexes. Our results suggest that AP-3 diverges from the model by which AP-1 and AP-2 adaptors bind to clathrin cages for vesicle biogenesis via the C-terminus of β adaptins with the terminal domain of clathrin-heavy chain (Lemmon and Traub, 2012).

**FIGURE 6:** Acute perturbation of clathrin function does not prohibit synaptic-like microvesicle formation after release of a brefeldin A block. PC12 cells stably expressing mCh-FKBP-CLC were treated for 2 h with brefeldin A (BFA) or vehicle control (EtOH) at 37°C. After this 2-h treatment, BFA-treated cells were either transferred to 4°C (BFA) or extensively washed at 4°C and then incubated with AP21087 (BFA-AP20187) or vehicle control (BFA-EtOH) for additional 2 h at 37°C. SLMVs sediment to the middle of 5–20% glycerol velocity gradients. Fractions from this gradient were loaded onto SDS–polyacrylamide gels for Western blot and densitometry quantifications. Immunoblot (IB) for SV2 and VAMP7 was used to track SLMVs. (A, A') Densitometry quantification of fraction signal per total signal in BFA-treated cells (white circles) as compared with EtOH-only treated cells (black circles). (B, B') Densitometry quantification of fraction signal per total signal in BFA-EtOH–treated cells (black circles). (C, C') Densitometry quantification of fraction signal per total signal in BFA-AP20187–treated cells (white circles) as compared with BFA-AP20187–treated cells (black circles). (D, E) Western blot of VAMP7 and SV2, respectively, from EtOH-, BFA-, BFA-EtOH–, and BFA-AP20187–treated cells.
reconstituted with just recombinant ARF1 and purified AP-3. A variable not controlled in these cell-free assays, however, is the contribution of donor membrane–bound clathrin to the reaction (Faundez et al., 2012; Royle, 2012). Alternatively, clathrin binding to AP-3 could be eliminated by treating the entire ear domain containing the clathrin box (pβ3AΔStop) before clathrin cages for vesicle biogenesis via the C-terminus of β adaptins with the terminal domain of clathrin heavy chain (Edeling et al., 2006; Kantehti et al., 2003). Collectively, the evidence supports our contention that clathrin–AP-3 interactions differ from those between clathrin and the adaptor complexes AP-1 and AP-2.

A question that arises from our data concerns the extent to which the functionality of a clathrin–AP-3 association observed in PC12 SLMV budding from endosomes reflects other putative AP-3–dependent budding events. Nearly 40% of all AP-3 immunoreactivity in cells is present in endosomes (Peden et al., 2004; Theos et al., 2005). A similar amount of AP-3, however, associates to tubules-vesicles not identified as endosomes, and 4–9% associates with the trans-Golgi network (Peden et al., 2009; Zlatic et al., 2011; Gokhale et al., 2012). This leaves open the possibility that there may be additional modalities of AP-3-dependent budding distinct from vesicle generation from endosomes, such as the formation of large, dense secretory vesicles from the Golgi complex (Asensio et al., 2010), where AP-3 and clathrin may interact in a productive manner.

MATERIALS AND METHODS

Antibodies and constructs

Anti-clathrin heavy chain was purchased from EMD Millipore (Billerica, MA; CP45, clone: X22) and BD Transduction Laboratories (PASadena, CA; 610499). Anti-clathrin light chain was purchased from EMD Millipore (AB9884) and Covance (Berkeley, CA; MMS-423P, clone: CON.1). Anti-adaptin α (610501), anti-adaptin γ (610385), and EEA1 (610456) were purchased from BD Transduction Laboratories. The AP36 SA4, c-myc 9E10, and SV2 10H antibodies, developed by Andrew Peden, J. Michael Bishop, and Kathleen M. Buckley, respectively, were obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Department of Iowa City, IA). Anti-synaptophysin was purchased from EMD Millipore (MAB5258, clone: SY38). Anti-AP3β (13384-1-AP) and anti-pallidin (10981-1-AP) were purchased from Protein Tech Group (Chicago, IL). Anti-mCherry/DSRed was purchased from Clontech (Mountain View, CA; 632496). Anti-GFP was purchased from AVEs Labs (Tigard, OR; GFP-mCherry/DsRed) and Alexa Fluor 488- and 555–conjugated anti-chicken (A11039), anti-mouse (A21212) and A21127), and anti-rabbit (A11034 and A21429) were purchased from Invitrogen (Carlsbad, CA).
Peptide directed against the AP3 δ SA4 antibody antigen binding site (AQQQ/DEVTEEMPEALPSGDEB/P/P/P/PYRRA) was obtained from the Emory University Microchemical Facility (Atlanta, GA) and Invitrogen (EvoQuest Team, Carlisbad, CA).

Clathrin heavy chain (RHS39799577067) and mutated (RHS397998822549) pLKO.1 shRNA constructs were purchased from Open Biosystems (Huntsville, AL). The constructs mCherry-FKBP-CLC and EGFP-Rab5-Q79L have been described (Claire et al., 2008; Zlatic et al., 2011).

Cell culture, transfection, and infection

HEK293 and SH-SY5Y cells (American Type Culture Collection, Manassas, VA) cultured in DMEM (HyClone, Logan, UT) containing 10% fetal bovine serum (HyClone) and 100 μg/ml penicillin and streptomycin (HyClone) and PC12 cells (American Type Culture Collection) cultured in DMEM containing 10% donor equine serum (HyClone), 5% fetal bovine serum, and 100 μg/ml penicillin and streptomycin were incubated at 37°C and 10% CO2. Generation and culture of Ap3b<sup>loclpe</sup> or Ap3b<sup>hoclpe</sup> rescued with either recombinant wild-type β3A or β3A mutations ablating putative clathrin-binding determinants was as described (Peden et al., 2002).

For transient transfections, HEK293 cells in wells of six-well plates were incubated with 1 μg of DNA in OptiMEM (Life Technologies, Grand Island, NY) containing 0.5% Lipofectamine 2000 (Invitrogen) for 4 h, followed by incubation with culture media. For stable transfections, PC12 cells were transfected as described in transient transfections, followed by 0.2 mg/ml G418 (Invitrogen) drug selection. Selected cells were serially diluted, and clonal populations were maintained in PC12 culture media supplemented with 0.1 mg/ml G418.

For lentiviral infection, lentivirus containing shRNA constructs were prepared by the Emory University Viral Vector Core. Antibiotic-free culture medium containing 1 μl of high-titer lentivirus was incubated with HEK293 or SH-SY5Y cells for 24 h, followed by incubation for 6 d with culture medium supplemented with 0.1 mg/ml selection drug, hygromycin B (Invitrogen), in 10-cm culture plates.

Acute clathrin perturbation and clathrin-coated vesicle fractionation

HEK293 or PC12 cells expressing the mCh-FKBP-CLC construct were grown to confluence. Cells were incubated for 2 h at culture conditions in medium supplemented with 50 nM AP20187 (B/B Homodimerizer 635060; Clontech) or 0.05% ethanol vehicle control (Zlatic et al., 2011). HEK293 cells infected with lentivirus containing scramble or clathrin heavy-chain shRNA constructs and transiently expressing mCh-FKBP-CLC, SH-SY5Y cells infected with lentivirus containing scramble or mutated shRNA constructs, and PC12 cells stably expressing mCh-FKBP-CLC with acute clathrin perturbation were prepared for clathrin-coated vesicle fractionation as previously described (Girard et al., 2004). Fractions were analyzed by either Western blot or Coomassie staining of 4–20% Criterion polyacrylamide gels (Bio-Rad, Hercules, CA).

DSP cross-linking and immunomagnetic precipitation

HEK293 and PC12 cells expressing mCh-FKBP-CLC were prepared for DSP cross-linking, followed by immunomagnetic precipitation as previously described (Salazar et al., 2009; Zlatic et al., 2010, 2011; Gokhale et al., 2012; Perez-Cornejo et al., 2012). The resulting isolated proteins were analyzed by Western blot of 4–20% Criterion polyacrylamide gels.

Brefeldin A/AP20187 treatment followed by synaptic-like microvesicle fractionation

PC12 cells expressing mCh-FKBP-CLC were grown to confluence in 10-cm plates, moved to an ice bath at 4°C, and washed three times in ice-cold phosphate-buffered saline (PBS) 1 mM MgCl2/0.1 mM CaCl2. Sequential drug-treated cells were incubated with warm DMEM supplemented with 10 mg/ml brefeldin A (Epicentre Bio-technologies, Madison, WI) for 2 h at 37°C. Plates were then moved to an ice bath at 4°C and washed for 5 min with ice-cold DMEM three times. Cells were then incubated with ice-cold DMEM supplemented with either 50 nM AP20187 or 0.05% ethanol vehicle control for 15 min on an ice bath at 4°C to allow for drug equilibration. Cells were then moved to 37°C water bath for 10 min to quickly warm media and then to 37°C incubator for 2 h. Single drug-treated cells were incubated with warm DMEM supplemented with 10 mg/ml brefeldin A or 1% ethanol vehicle control for 2 or 4 h at 37°C. After incubation, cells were placed directly on an ice bath at 4°C and washed two times with ice-cold PBS/1 mM MgCl2/0.1 mM CaCl2 with subsequent synaptic-like microvesicle fractionation.

Synaptic-like microvesicle fractionation was performed as previously described (Faundez et al., 1997; Faundez and Kelly, 2000; Clift-O’Grady et al., 1998). Briefly, cells were lifted in intracellular buffer (38 mM potassium aspartate, 38 mM potassium glutamate, 38 mM potassium gluconate, 20 mM 3-(N-morpholino)propanesulfonic acid–KOH, pH 7.2, 5 mM reduced glutathione, 5 mM sodium carbonate, 2.5 mM magnesium sulfate, 2 mM ethylene glycol tetraacetic acid) and sedimented for 5 min at 800 × g at 4°C in a table-top centrifuge. Cell pellet was suspended in 300 μl of Intracellular buffer supplemented with Complete antiprotease (Roche, Indianapolis, IN). Homogenate was prepared with a 12-μm clearance cell cracker with intracellular buffer supplemented with Complete antiprotease at 4°C. Equal protein load from homogenate was centrifuged at 1000 × g for 5 min at 4°C in a table-top centrifuge, generating the first supernatant (S1) and pellet (P1). S1 was centrifuged at 27,000 × g for 35 min at 4°C in a Sorvall SS34 rotor (Thermo Scientific, Waltham, MA) to generate the second supernatant (S2) and pellet (P2). Equal volumes of the S2 were overlaid on a 5–25% glycerol gradient prepared in intracellular buffer generated by a Bio-comp Gradient Master (Biocomp, Frederickton, Canada). Gradients were then centrifuged at 218,000 × g for 75 min at 4°C in a Beckman SW55 rotor (Beckman Coulter, Palo Alto, CA). Aliquots of the glycerol gradient after centrifugation were analyzed by Western blot on 4–20% Criterion polyacrylamide gels (Bio-Rad).

Immunofluorescence, microscopy, and analysis

Coverslips were prepared as previously described (Claire et al., 2008; Zlatic et al., 2011). Cells were seated on Matrigel-coated (BD Bioscience, San Jose, CA) coverslips. Cells were washed twice in PBS/1 mM MgCl2/0.1 mM CaCl2 and fixed with 4% paraformaldehyde in PBS. Cells were blocked, permeabilized, and probed with primary and secondary antibody in block buffer (PBS containing 15% donor equine serum [HyClone], 2% bovine serum albumin [HyClone], 1% fish gelatin [Sigma-Aldrich, St. Louis, MO], and 0.02% saponin [Sigma-Aldrich]). After secondary antibody probing, cells were washed twice in block buffer and once with PBS supplemented with 1 mM MgCl2 and 0.1 mM CaCl2 and mounted on slides with Gelvatol.

Deconvolution microscopy was carried out as previously described on a 200M inverted microscope (Carl Zeiss, Thornwood, NY) and Sedat filter set (Chroma Technology, Rockingham, UT) run with a multiwavelength, sequential capture, wide-field, three-dimensional microscopy system from SlideBook 4.0 OS X software (Intelligent


Statistical analysis
Experimental conditions were compared using Synergy KaleidaGraph, version 4.1.3 (Reading, PA), or StatPlus Mac Built.6.0pre/Universal (AnalystSoft, Vancouver, Canada). Data are presented as boxplots displaying the four quartiles of the data, with the “box” comprising the two middle quartiles, separated by the median. The upper and lower quartiles are represented by the single lines extending from the box.

ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health (GM077569 and NS42599) and the Emory University Research Committee to V.F. PVR was supported by National Research Service Award Fellowship F31NS0765. This work was supported in part by the National Institute of Environmental Health Sciences of the National Institutes of Health under Awards P01ES016731 (V.F.) and T32ES012870 (S.Z.). This research project was supported in part by the Emory University Integrated Cellular Imaging Microscopy Core and Viral Cores of the Emory Neuroscience National Institute of Neurological Disorders and Stroke Core Facilities Grant P30NS055077

REFERENCES


